PT - JOURNAL ARTICLE AU - Rajaram, Smitha AU - Swift, Andrew J AU - Telfer, Adam AU - Hurdman, Judith AU - Marshall, Helen AU - Lorenz, Eleanor AU - Capener, David AU - Davies, Christine AU - Hill, Catherine AU - Elliot, Charlie AU - Condliffe, Robin AU - Wild, Jim M AU - Kiely, David G TI - 3D contrast-enhanced lung perfusion MRI is an effective screening tool for chronic thromboembolic pulmonary hypertension: results from the ASPIRE Registry AID - 10.1136/thoraxjnl-2012-203020 DP - 2013 Jul 01 TA - Thorax PG - 677--678 VI - 68 IP - 7 4099 - http://thorax.bmj.com/content/68/7/677.short 4100 - http://thorax.bmj.com/content/68/7/677.full SO - Thorax2013 Jul 01; 68 AB - Background Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of pulmonary embolism potentially curable by surgery. Perfusion scintigraphy is currently advocated as the imaging modality of choice to exclude CTEPH due to its high sensitivity. We have evaluated the diagnostic utility of lung perfusion MRI. Methods Consecutive patients attending a pulmonary hypertension referral centre undergoing lung perfusion MRI, perfusion scintigraphy, CT pulmonary angiography (CTPA) and right heart catheterisation within 14 days were identified. Results Of 132 patients, 78 were diagnosed as having CTEPH. Lung perfusion MRI correctly identified 76 patients as having CTEPH with an overall sensitivity of 97%, specificity 92%, positive predictive value 95% and negative predictive value 96% compared with perfusion scintigraphy (sensitivity 96%, specificity 90%) and CTPA (sensitivity 94%, specificity 98%). No cases of surgically accessible CTEPH were missed with either modality. Conclusions Lung perfusion MRI has high sensitivity equivalent to perfusion scintigraphy in diagnosing CTEPH but does not require ionising radiation, making it an attractive initial imaging modality to assess patients with suspected CTEPH.